Obstructive sleep apnea (OSA) is a significant risk factor for systemic hypertension and other cardiovascular diseases. While this relationship has been firmly established, an understanding of how OSA leads to hypertension is poorly understood. Recently, scientists have begun to recognize that neuroinflammation is an important factor in the development of hypertension, including that hypertension associated with OSA. However, the underlying source and the steps that illicit neuroinflammation with OSA is unknown. In this proposal, we will develop the idea that the gut microbiota is responsible for initiating and maintaining neuroinflammation required for the development of hypertension. In recent years, it has been recognized that a microbiota-gut-brain axis exists, whereby microorganisms residing in the gut play a critical role in regulating brain homeostasis and function. We propose the overall hypothesis that OSA promotes neuroinflammation and hypertension through gut dysbiosis and modification of the microbiota-gut-brain axis. We have found through preliminary studies that OSA alters the makeup of the gut microbiota, leads to gut barrier disruption and the introduction of bacteria and endotoxins into the systemic circulation. We have also shown that OSA promotes a pro-inflammatory phenotype in innate immune cells in both the gut and brain. Additionally, we have linked OSA- induced dysbiosis to the development of hypertension by demonstrating that the hypertensive phenotype can be transferred to a normotensive rat by transplantation with a dysbiotic microbiota. Lastly, we provide the foundation for a therapeutic strategy using oral prebiotics and probiotics, which were able to prevent dysbiosis, reduce gut inflammation and neuroinflammation, and prevent OSA-induced hypertension. The main goal of this proposal is to understand how components of the microbiota-gut-brain axis are altered by OSA and contribute to neuroinflammation and hypertension, with a focus on activated immune cell signaling (Aim 1), altered metabolite signaling (Aim 2), and methods of preventing OSA-induced hypertension (Aims 1-3). In each aim we will manipulate the microbiome by diet or next generation probiotics to determine the effects on OSA-induced hypertension, a disease becoming more common in our overweight and aging population.

Public Health Relevance

Individuals suffering from obstructive sleep apnea (OSA), a condition where the upper airway repeatedly collapses during sleep to produce apneas, are at risk for developing hypertension. The proposed studies will examine the role of gut dysbiosis in the development of OSA-induced hypertension. Understanding the associations between gut dysbiosis and hypertension could result in new and novel therapeutic interventions to favorably alter the gut microbiota.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL134838-02
Application #
9618262
Study Section
Hypertension and Microcirculation Study Section (HM)
Program Officer
OH, Youngsuk
Project Start
2018-01-01
Project End
2022-12-31
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Ganesh, Bhanu P; Nelson, James W; Eskew, Joshua R et al. (2018) Prebiotics, Probiotics, and Acetate Supplementation Prevent Hypertension in a Model of Obstructive Sleep Apnea. Hypertension 72:1141-1150